TRANSLATE-TIMI 70 is a phase 2b trial testing multiple doses of vupanorsen, an antisense oligonucleotide (ASO) against angiopoietin-like 3 (ANGPTL3) mRNA, for safety and efficacy in non-HDL-C lowering.
TRANSLATE on ClinicalTrials.gov
An Academic Research Organization of Brigham & Women's Hospital and An Affiliate of Harvard Medical School
